I think most RAC investors are aware of this information. We know of the changes going on in the AML market which is why we are moving to a low intensity use of bisantrene in AML. The upcoming AML trial will use bisantrene as a low intensity treatment that will be able to be used in ‘unfit’ patients. Of course this approach requires that we have a form of bisantrene that can be used in an outpatient environment and this is exactly what RC220 offers.
CPACS: Research, Results, Market Comparisons, and Valuations, page-82
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.165(11.5%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.61 | $1.46 | $245.3K | 161.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 229 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 1226 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |